"SANKYO" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonDaiichi Sankyo (OTCMKTS:DSNKY) Trading Down 0.8% - What's Next? - MarketBeat
Daiichi Sankyo (OTCMKTS:DSNKY) Trading Down 0.8% - What's Next? MarketBeat
AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer - insights.citelin...
AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer insights.citeline.com
Will Sankyo’s (TSE:6417) Dividend Shift Reveal More About Its Capital Allocation Priorities? - si...
Will Sankyo’s (TSE:6417) Dividend Shift Reveal More About Its Capital Allocation Priorities? simplywall.st
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA - Pharmaceutical Technology
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA Pharmaceutical Technology
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd - BioSpace
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - ...
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. BioPharma Dive
Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-frien...
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer - Seeking Alpha
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer Seeking Alpha
Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for...
Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe - Oncodaily
Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe Oncodaily
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 O...
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 Outcomes Applied Clinical Trials
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved Results in Breast Cancer Trial - MarketScreener
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved Results in Breast Cancer Trial MarketScreener
MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial - Clinical Trials Arena
MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial Clinical Trials Arena
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades - Bloomberg.com
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades Bloomberg.com
Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' - Fierce P...
Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' Fierce Pharma
AstraZeneca, Daiichi Sankyo Enhertu plus pertuzumab sBLA granted priority review - TipRanks
AstraZeneca, Daiichi Sankyo Enhertu plus pertuzumab sBLA granted priority review TipRanks
Should You Buy Sankyo Co., Ltd. (TSE:6417) For Its Upcoming Dividend? - simplywall.st
Should You Buy Sankyo Co., Ltd. (TSE:6417) For Its Upcoming Dividend? simplywall.st
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's - simplywal...
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's simplywall.st
Sankyo (TSE:6417) Has Announced A Dividend Of ¥45.00 - simplywall.st
Sankyo (TSE:6417) Has Announced A Dividend Of ¥45.00 simplywall.st
#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancer - Endpoints News
#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancer Endpoints News
Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation - Nasdaq
Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation Nasdaq
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a Ne...
Okuzawa to succeed Sunao Manabe as Daiichi Sankyo CEO - Pharmaceutical Technology
Okuzawa to succeed Sunao Manabe as Daiichi Sankyo CEO Pharmaceutical Technology
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enher...
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab Applied Clinical Trials
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo - Pharmaceutical Technology
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo Pharmaceutical Technology
Daiichi Sankyo (TSE:4568): Valuation Insights After Breakthrough FDA Nod for R-DXd in Ovarian Can...
Daiichi Sankyo (TSE:4568): Valuation Insights After Breakthrough FDA Nod for R-DXd in Ovarian Cancer simplywall.st
Daiichi Sankyo joins Milner Therapeutics Consortium - Cambridge Network
Daiichi Sankyo joins Milner Therapeutics Consortium Cambridge Network
Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline - Medical Marketing a...
Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline Medical Marketing and Media
Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highl...
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings - B...
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings BioSpace
AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy - ...
AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy MedCity News
Sankyo Co. Hits Day Low of JPY 2,561.50 Amid Price Pressure - Markets Mojo
Sankyo Co. Hits Day Low of JPY 2,561.50 Amid Price Pressure Markets Mojo
Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan - MSN
Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan MSN
Sankyo Co. Announces Strong Financial and Dividend Forecasts for FY2026 - TipRanks
Sankyo Co. Announces Strong Financial and Dividend Forecasts for FY2026 TipRanks
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data - BioSpace
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data BioSpace
Is There Still Opportunity in Sankyo After Five Years of 526% Gains? - simplywall.st
Is There Still Opportunity in Sankyo After Five Years of 526% Gains? simplywall.st
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...
Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology
Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China Pharmaceutical Technology
Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival - Fierce Ph...
Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival Fierce Pharma
Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang - BioSpace
Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang BioSpace
Daiichi Sankyo/Merck’s I-Dxd Tipped For Fast Track After Lung Cancer Results - insights.citeline.com
Daiichi Sankyo/Merck’s I-Dxd Tipped For Fast Track After Lung Cancer Results insights.citeline.com
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-...
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO Yahoo Finance
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 32.2% in August - Mark...
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 32.2% in August MarketBeat
TABLE-Sankyo (pinball) -2025/26 div forecast - TradingView
TABLE-Sankyo (pinball) -2025/26 div forecast TradingView
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan - BioPharm International
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan BioPharm International
Daiichi Sankyo and Merck withdraw BLA for patritumab deruxtecan in US - World Pharmaceutical Fron...
Daiichi Sankyo and Merck withdraw BLA for patritumab deruxtecan in US World Pharmaceutical Frontiers
Daiichi Sankyo at ASCO 2025: Markus Kosch on Advancing Patient Outcomes Through Scientific Innova...
We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings - simplywa...
We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings simplywall.st
Merck and Daiichi Sankyo Launch Global Phase III Trial of Novel Antibody Drug Conjugate in Advanc...
Merck and Daiichi Sankyo Launch Global Phase III Trial of Novel Antibody Drug Conjugate in Advanced Esophageal Squamous Cell Carcinoma Applied Clinical Trials
Milestone launch for Daiichi Sankyo’s Datroway in Japan - The Pharma Letter
Milestone launch for Daiichi Sankyo’s Datroway in Japan The Pharma Letter
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC - OncLive
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC OncLive
Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint - Fi...
Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint Fierce Biotech
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment - Pharmaceutical Technology
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment Pharmaceutical Technology
Japanese Drugmaker Daiichi Sankyo Breaks Ground on USD154 Million ADC Facility in Shanghai - Yica...
Japanese Drugmaker Daiichi Sankyo Breaks Ground on USD154 Million ADC Facility in Shanghai Yicai Global
Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage - Fierce Pharma
Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage Fierce Pharma
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer - PMLiVE
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer PMLiVE
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer The Daily Upside
Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio - Endpoi...
Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio Endpoints News
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC - Pharmaceutical Technology
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC Pharmaceutical Technology
At ASCO 2025, attendees see reason for hope, despite worries - statnews.com
At ASCO 2025, attendees see reason for hope, despite worries statnews.com
Daiichi Sankyo Announces New CEO - Pharmaceutical Executive
Daiichi Sankyo Announces New CEO Pharmaceutical Executive
AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ ...
AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ Breast... Medical Dialogues
High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF) - Seeking Alpha
High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF) Seeking Alpha
Daiichi Sankyo - drugdiscoverytrends.com
Daiichi Sankyo drugdiscoverytrends.com
AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway - Drug Store News
AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway Drug Store News
AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. - ...
AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. The Wall Street Journal
Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt? - simplywall.st
Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt? simplywall.st
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's - simplywal...
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's simplywall.st
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo - BioSpace
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo BioSpace
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m - Pharmaceutical Technology
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Pharmaceutical Technology
Could The Market Be Wrong About Daiichi Sankyo Company, Limited (TSE:4568) Given Its Attractive F...
Could The Market Be Wrong About Daiichi Sankyo Company, Limited (TSE:4568) Given Its Attractive Financial Prospects? simplywall.st
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to A...
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer - PM...
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer PMLiVE
Daiichi Sankyo doses first subject in Phase III AML therapy trial - Clinical Trials Arena
Daiichi Sankyo doses first subject in Phase III AML therapy trial Clinical Trials Arena
Daiichi Sankyo celebrates its historic connection to the National Cherry Blossom Festival - WJLA
Daiichi Sankyo celebrates its historic connection to the National Cherry Blossom Festival WJLA
Daiichi Sankyo and AstraZeneca’s Enhertu gains breakthrough therapy status - Pharmaceutical Busin...
Daiichi Sankyo and AstraZeneca’s Enhertu gains breakthrough therapy status Pharmaceutical Business review -
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion - BioSpace
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion BioSpace
Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha
Daiichi Sankyo: Good Diversification Tool For U.S. Investors Seeking Alpha
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Business Wire
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer Business Wire
Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to De...
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Gl...
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH Business Wire
Daiichi Sankyo exec on purposeful data collection - Clinical Trials Arena
Daiichi Sankyo exec on purposeful data collection Clinical Trials Arena
Merck and Daiichi Sankyo Withdraw FDA Application for HER3-Targeting Lung Cancer Drug After Trial...
Merck and Daiichi Sankyo Withdraw FDA Application for HER3-Targeting Lung Cancer Drug After Trial Failures geneonline.com
MSD and Daiichi Sankyo pull HER3-DXd's FDA filing - pharmaphorum
MSD and Daiichi Sankyo pull HER3-DXd's FDA filing pharmaphorum
Daiichi Sankyo joins Milner Therapeutics Consortium - Business Weekly
Daiichi Sankyo joins Milner Therapeutics Consortium Business Weekly
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer - PM...
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer PMLiVE
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer - MedCity News
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer MedCity News
AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer - PMLiVE
AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer PMLiVE
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial - Yahoo Finance
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial Yahoo Finance
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period - BioSpace
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period BioSpace
Daiichi Sankyo stock jumps on strong earnings and buyback plan - Investing.com
Daiichi Sankyo stock jumps on strong earnings and buyback plan Investing.com
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win - BioSpace
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win BioSpace
Ahmed Kotb has joined Daiichi Sankyo as the Head of Global Oncology Medical Affairs - Oncodaily
Ahmed Kotb has joined Daiichi Sankyo as the Head of Global Oncology Medical Affairs Oncodaily
Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor - PR Newswire
Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor PR Newswire
Daiichi Sankyo names chief operating officer Sunao Manabe as new CEO - FirstWord Pharma
Daiichi Sankyo names chief operating officer Sunao Manabe as new CEO FirstWord Pharma
Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress - Morn...
Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress Morningstar
NTK Raises Damages Claim Against Daiichi Sankyo To A Whopping 184 Billion Yen - Finimize
NTK Raises Damages Claim Against Daiichi Sankyo To A Whopping 184 Billion Yen Finimize
AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer - PMLiVE
AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer PMLiVE
AstraZeneca selects Daiichi Sankyo as US marketing partner for Movantik - FirstWord Pharma
AstraZeneca selects Daiichi Sankyo as US marketing partner for Movantik FirstWord Pharma
Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030 - koreabiomed.com
Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030 koreabiomed.com